🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› EU
Clinical trial register · European Union · CTIS

Recently authorised EU trials

The most recently authorised trials on the EU Clinical Trials Information System (CTIS), the single register for every trial run under the EU Clinical Trials Regulation (536/2014). CTIS holds a far larger historical archive than any one list can usefully show — this register states both numbers rather than picking one.

Download CSV
Source: EMA Clinical Trials Information System (CTIS). Showing the 2500 most recently authorised of 12445 total CTIS records — a stated recency window, not the full historical archive. Synced 19 Sep 2026, 04:26 UTC
2500
Shown in this register
most recently authorised
12,445
Total on CTIS
full historical archive
745
Phase III
within the shown window
Top member states
Spain 1023 France 890 Germany 861 Italy 742 Poland 581 Netherlands 524
Narrow the registerReset
Phase
Phase I 558 Phase I/II 214 Phase II 726 Phase III 745 Phase IV 257
Lead sponsor
AstraZeneca AB 60 Assistance Publique Hopitaux De Paris 49 Merck Sharp & Dohme LLC 48 Pfizer Inc. 45 Novo Nordisk A/S 42
Member state
Spain 1023 France 890 Germany 861 Italy 742 Poland 581 Netherlands 524 Belgium 426 Czechia 327
All 28 states
214 of 2500 shown studies
Download
Phase
Study
Lead sponsor
Area
Member states
Decision
Phase I/II
A follow-up extension study of patients who completed the U-LaserPrint-1 clinical trial to evaluate the long-term safety and efficacy of treatment with InvivoLPrint-U.
2026-527804-26-00Muscle-invasive bladder cancer (MIBC) patients, eligible fo…
Phosprint S.A.
Neoplasms
Greece
17/09/2026
Phase I/II
A study assessing the safety, tolerability, pharmacokinetics and efficacy of single and multiple doses of NNC0638-0355 in participants with overweight or obesity
2026-526797-16-00Obesity and overweight
Novo Nordisk A/S
Nutritional and Metabolic Diseases
Netherlands
14/09/2026
Phase I/II
A Phase Ia/II Randomized Controlled Trial of Daratumumab Alone Versus Daratumumab Plus Abatacept for resistant active Antibody-Mediated Rejection in Kidney Transplant Recipients
2026-526730-73-00active Antibody-Mediated Rejection in Kidney Transplant Re…
Fundacio Hospital Universitari Vall D’Hebron Institut De Recerca
Immune System Diseases
Spain
08/09/2026
Phase I/II
A Long-Term Follow-Up Study to Assess the Safety and Efficacy of B-Cell-Directed Therapy in Patients with Systemic Autoimmune Disease (B-CARE)
2026-526888-37-00systemic autoimmune diseases
Universitaetsklinikum Erlangen AöR
Immune System Diseases
Germany
07/09/2026
Phase I/II
Phase 1/2, first-in-human, randomized, double-blind, reference-controlled study to evaluate the safety and immunogenicity of an extemporaneously mixed Combo Inactivated Influenza Vaccine (Green Cross [GC]-IIV; 15µg of each hemagglutinin [HA])/OVX836 (480µg), in comparison to GC-IIV (15µg of each HA) concomitantly administered with OVX836 (480µg), GC-IIV alone (15 µg each HA), OVX836 alone (480µg), and a licensed reference trivalent IIV (Vaxigrip®; 15µg of each HA), administered intramuscularly (IM) in healthy participants
2026-526939-19-00Influenza disease
Osivax
Virus Diseases
Belgium
04/09/2026
Phase I/II
​​Perioperative zanidatamab combined with chemotherapy in HER2-positive locally advanced operable gastroesophageal adenocarcinoma (GEA): a Phase 1b/2a single-arm trial​
2025-523483-20-00Gastroesophageal adenocarcinoma (GEA)
UZ Leuven
Neoplasms
Belgium
31/08/2026
Phase I/II
An Open-Label, Multicenter Phase 1/2 Study to Assess the Safety, Tolerability, and Efficacy of Intracochlear Ascending Dose Injections of SENS-601 Followed by Expansion Cohort in Pediatric Population With Hearing Loss Related to Biallelic Pathogenic Variation(s) of GJB2, As Well As to Demonstrate the Performance of the Administration System, Its Safety, Its Clinical Benefit, and Its Usability.
2026-525698-38-00Hearing Loss Related to biallelic pathogenic variation (s) …
Sensorion
Otorhinolaryngologic Diseases
France
31/08/2026
Phase I/II
A Phase 1/2, Open-Label, Multicenter, Multi-cohort Study of S241656 as Monotherapy or in Combination with other Antileukemic Agents in participants with Selected Myeloid Malignancies
2025-525128-88-00Patients with Acute Myeloid Leukemia (AML), Myelodysplastic…
Institut De Recherches Internationales Servier IRIS
Neoplasms
Netherlands, Spain, Germany, Italy, France, Finland
27/08/2026
Phase I/II
A combined phase I/IIa trial to investigate the safety and pharmacokinetics of StaphAcute in healthy participants and patients with Staphylococcus aureus bacteremia - StaphAcute
2024-511586-10-01Phase IIa: patients with methicillin susceptible (MSSA) or …
University Of Cologne
Bacterial Infections and Mycoses
Germany
24/08/2026
Phase I/II
A Prospective Diagnostic Trial of Al[¹⁸F]F-NOTA-folate PET in Patients with Suspected Cardiac Sarcoidosis or Infective Endocarditis and Healthy Volunteers (FOL-CARD)
2026-526655-59-00Cardiac Sarcoidosis, Infective endocarditis
Turku University Hospital
Cardiovascular Diseases
Finland
24/08/2026
Phase I/II
A multicenter, non-therapeutic, interventional, long-term follow-up clinical trial to evaluate the safety of autologous PRAME-directed TCR T cell therapy IMA203 or IMA203CD8 in patients with previously treated, advanced and/or metastatic solid tumors
2026-525827-25-00Solid tumors
Immatics US Inc.
Neoplasms
Germany
21/08/2026
Phase I/II
Phase I/II trial of Dinutuximab beta in combination with Irinotecan and Rapamycin in pediatric, adolescents and adult patients with relapsed/refractory bone tumors. BONE DINIRRA
2026-525463-40-00osteosarcomas, chondrosarcomas, Ewing sarcomas, Ewing-like …
Les Hopitaux Universitaires De Strasbourg
Neoplasms
France
20/08/2026
Phase I/II
A Modular Open-label, Phase I/IIa Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of Ascending Doses of AZD4956 as Monotherapy, and in Combination with Anti-Cancer Agents in Participants with Advanced/Metastatic Homologous Recombination Repair Defective Solid Tumours (PARTHENON)
2025-524171-22-00Solid Tumors
AstraZeneca AB
Neoplasms
Spain
20/08/2026
Phase I/II
A Phase 1/2 Trial of TER-2013 in Patients with Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
2025-525036-34-00Solid Tumours
Terremoto Biosciences Inc.
Neoplasms
Spain, Ireland, Hungary, Romania, France, Portugal, Belgium, Poland
18/08/2026
Phase I/II
A Phase 1/2 Open-label, Multi-center Study to Evaluate the Safety and Clinical Activity of GSK5926371 in Adult Participants with Relapsed or Refractory B-cell Non-Hodgkin Lymphomas (B-NHL)
2025-524915-36-00Lymphoma, Non-Hodgkin
Glaxosmithkline Research & Development Limited
Neoplasms
Italy, Germany, Spain, Finland, France
17/08/2026
Phase I/II
An open-label phase I/II, single-center, interventional singlearm basket trial of UKT-CART19.1 in patients with relapsed/refractory autoimmune diseases
2024-519491-60-00ANCA associated vasculitis (AAV), Immune thrombocytopenic p…
Universitaetsklinikum Tuebingen AöR
Immune System Diseases
Germany
14/08/2026
Phase I/II
A two-part, randomised, double-blind, placebo-controlled, parallel-group, 12week trial investigating the safety, tolerability, pharmacokinetics and efficacy of XEN-D0501 in obese participants
2026-525869-42-00Obesity
Pila Pharma AB
Nutritional and Metabolic Diseases
Sweden
13/08/2026
Phase I/II
Preventive Dendritic Cell vaccination for Lynch Syndrome (PREVENT-Lynch)
2025-524046-10-00Lynch Syndrome
Radboud universitair medisch centrum Stichting
Digestive System Diseases
Netherlands
12/08/2026
Phase I/II
Bioequivalence clinical trial of two formulations of quetiapine.
2026-527162-72-00Healthy participants
Laboratorios Alter S.A.
Mental Disorders
Spain
11/08/2026
Phase I/II
Evaluation of Interference and Synergy of Anti-Circumsporozoite Antibodies on GA2-induced Immunity
2026-525353-37-00Plasmodium falciparum malaria
Leids Universitair Medisch Centrum (LUMC)
Parasitic Diseases
Netherlands
10/08/2026
Phase I/II
Trial to study the safety, pharmacokinetics and preliminary antitumour activity of ODM-216 in patients with cancer
2026-525864-17-00Advanced solid tumours
Orion Corporation
Neoplasms
Spain
06/08/2026
Phase I/II
A Phase 1b/2a first-in-human, multicentre, randomized, double-blind, placebo-controlled study of multiple ascending dose (Part1) followed by an open-label extension (Part2) to assess the safety, tolerability, and pharmacokinetics of intrathecally administered S233107 in participants with spinocerebellar ataxia type 3
2025-525111-17-00Spinocerebellar ataxia type 3
Institut De Recherches Internationales Servier IRIS
Nervous System Diseases
France, Denmark, Spain, Portugal
30/07/2026
Phase I/II
A Phase I/II, randomized, placebo-controlled, multi-arm, dose-finding study to evaluate the safety, efficacy and immunogenicity of an Acne mRNA vaccine candidate in adults with moderate to severe acne 18 to 45 years of age
2025-521740-38-00Acne
Sanofi Pasteur Inc.
Skin and Connective Tissue Diseases
Spain, Germany, Poland
29/07/2026
Phase I/II
Melanoma-TBK1-inhibitor enhanced Immuno Therapy with Checkpoint Inhibitors: a Phase IB/II Trial in Unresectable Stage III or Stage IV Cutaneous Melanoma
2026-526821-16-00Unresectable Stage III or Stage IV Cutaneous Melanoma
Karolinska University Hospital
Neoplasms
Sweden
28/07/2026
Phase I/II
Phase I/II Trial to Determine Safety and Efficacy of non-Viral Allogeneic Dual CD123/33-Chimeric Antigen Receptor CIK (CARCIK-CD123/33) Cells in Adult and Pediatric Patients with Relapse/Refractory Acute Myeloid Leukemia (AML) and Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
2025-524977-18-00Acute myeloid leukemia and Blastic plasmacytoid dendritic c…
Fondazione Tettamanti, Fondazione IRCCS San Gerardo Dei Tintori
Neoplasms
Italy
27/07/2026
Rows per page Showing 1–25 of 214
1 2 3 Next
Cite this view

Priya Life Science (2026). EU Clinical Trials Register (CTIS), filtered. Derived from the EMA Clinical Trials Information System. Retrieved 19 September 2026. https://priyalifescience.com/clinical-trials-europe

Query this register directly
GET /api/export.php?register=trials-eu&format=json Try it now →
Listing here is informational and not medical advice; eligibility is determined by each study team. Looking for Irish sites? See the Ireland, UK or USA registers. For approved medicines, see the EMA Approvals Tracker.